- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Esaote Launches Updated S-Scan Open MRI System
The update of the S-scan magnetic resonance imaging (MRI) system reportedly offers an improved ergonomic design, algorithms to enhance image quality and reduced scan times.
Offering a variety of technological improvements to help facilitate optimal imaging and radiology workflows, Esaote has introduced the S-scan Open magnetic resonance imaging (MRI) system, an update to the company’s established S-scan MRI platform.
Esaote said the system’s combination of image acquisition and reconstruction capabilities through technologies such as SpeedUp and TR reduction enables clinicians to reduce artifacts, background noise and scan times. The combination of True-Motion technology with the S-scan Open MRI’s open magnet design allows one to capture real-time images of joint movements, according to Esaote.
The company adds that a complete set of RF coils, included with the S-scan Open MRI system, may facilitate improved spatial resolution, a high signal-to-noise ratio (SNR) and maximum sensitivity to anatomies being imaged.
Esaote added that key ergonomic features of the MRI system include a wide asymmetric rotating table, which promotes easy setup as well as maximum comfort and stability with patient positioning.
‘With S-scan Open, we have relied on Esaote’s latest technology in terms of the hardware and software platform. It has been specifically reengineered to face the challenging requirements of musculoskeletal exams,” said Massimo Olmi, the MRI marketing director of Esaote.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Diffusion-Weighted MRI and Neoadjuvant Chemotherapy for Rectal Cancer: What New Research Reveals
September 3rd 2024In a comparison of imaging assessments to gauge the effectiveness of neoadjuvant chemotherapy for rectal adenocarcinoma, researchers found the combination of diffusion-weighted imaging and MR tumor regression grading had a 90 percent area under the curve (AUC) and a negative predictive value (NPV) of 93 percent.
